TheraRadar
← Back
Data updated: Mar 29, 2026

UNITED THERAP

RespiratoryCardiovascularOncology
Specialty

UNITED THERAP is a specialty pharmaceutical company focused on Respiratory, Cardiovascular, Oncology. Key products include UNITUXIN.

2002
Since
5
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

UNITUXIN
dinutuximab
GD2 1 indications · 2015
TYVASO DPI
treprostinil
Cardiovascular
3 indications · 2022
ORENITRAM
treprostinil diolamine
Cardiovascular
1 indications · 2013

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

UNITUXIN 2025-10-10
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 55%
3 drugs Phase 3: 13 Phase 2: 7 Phase 1: 6
Cardiovascular 44%
3 drugs Phase 3: 9 Phase 2: 7 Phase 1: 5
Oncology 1%
0 drugs Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Oncology, Cardiovascular, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular
Boehringer Ingelheim big-pharma
Oncology, Respiratory, Cardiovascular
GE HEALTHCARE specialty
Cardiovascular, Oncology, Respiratory
BRACCO specialty
Cardiovascular, Oncology, Respiratory